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background mortality may be high in these pts, particularly when followed
long-term. Five-year (5 yr) cause of death, determined from autopsy and
death certificate information, was analyzed in 2123 coronary angioplasty pts
(mean age at baseline= 57.5) without acute Ml in the NHLBI PTCA Registry.
There were 200 deaths (9.4%) at 5 yr fu with 52.5% attributed to cardiac
causes. Pts with low ejeetion fraction, prior bypass surgery, inoperable/high
surgical risk, or multi-vessel disease had elevated 5 yr cardiac mortality.
Pts with history of diabetes, congestive heart failure or severe concomitant
disease had elevated rates of both cardiac and non-cardiac mortality. As
length of fu increased, a crossover from cardiac to non-cardiac mortality was
pronounced in older pts (table). In multivariate analysis, age>= 65 strongly
predieted 5 yrrie.kof non-cardiac mortality (RR =3.42, p c 0.001) but was not
predictive of cardiac mortality. Conclusions: Both all-cause and Cardiac-only
mortality should be evaluated in coronary intewention studies involving older
pts and long-term fu. Otherwise, conclusions related to treatment efficacy
and prognostic factors may be inappropriate. Similarly, non-fatal cardiac
outcomes (i.e. anginal atatus, repeat revascularization) seem particularly
important in corona~ Intervention studies involving older pts and long-term
fu.
Patienl age CumulativeCardiac (C)/Non-Cardiac (NC)
at baseline MortalityRats Ratio at Follow-upIntervals
6 men. 1 yr. 2 yr. 3 yr. 4 yr. 5 yr.
<65 vears 5.0 t ,s 2.0 1,7 1,6 1.5
>65 years 1.9 1.4 1,5 1.0 0,s 0.s
Cum. deaths C/NC 26/12 35122 5S/32 68/52 s7i74 lo5te5
11031-621 ~;~~g~:J;:AE.~~W.. S.~.y~fS..d.V.V
EUROASPIRE Study Group. Cardiac Medicine, National i-feartand Lung
/nstitute, /mperfa/ College School of Medicine, University of London, UK,
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A European survey in nine countries (Czech Republic, Finland, France, Ger-
many, Hungary, Italy, Netherlands, Slovenia and Spain) was undertaken to
measure the potential for secondary prevention of coronary heart disease.
Consecutive patients (S 70 years) from four diagnostic groups – CABG,
PTCA, AMI and acute myocardial ischaemia without infarction-were identi-
fiedfromthecentres and they were then invited forinterviewand examination
at least six montha after the acute procedure or event. 4663 medical records
were reviewed and 3569 (737.) patients atfended for interview. In all patients
combined the prevalence (range between centres) of risk faetor6at interview
was: 19% (13Y0Fin - 32Y0Ne) Currerdcigarette smokers; 25% (19% Net -
33% Fra) had a I.xxly mass index >30 kg/m2; 53% (48% Fra - 61% Cze)
had hypertension; 44% (36% Spa - 56% Ita) had a total cholesterol of ? 5.5
mmol/l; 18% (14% Ger - 27Y0Hun) were diabetic; and 5394 (33% Spa -
71% Fin) had a positive family histoty of CHD. Reported prophylactic drug
therapy was as follows: 87°A (72% Hun – 86% Ita) antiplatelets or anticoag-
ulants; 54% (35% Spa - 76% Fin) beta blockers; 307. (17% Fin - 46% Hun)
ACE inhibitors; 32% (22% Hun - 42% Fra) lipid lowering drugs; and 10%
(7% Fin - 16% Spa) anti-diabetic druge. There was considerable variation
in the prevalence of risk factors and drug use between centres and also
between diagnostic categories. In patients with coronary disease in Europe
there is still considerable medical potential to reduce the risk of a futiher
major ieehaemic event.
m1031 63 Air ForcefTexas Coronary AtheroscleroaiePrevention Study: Deeign and Baseline
Characteristics
E. Whitney, M. Clearfield, J.R. Downs, D.R. Shapiro, E.A. stein, p.A. Beerei
A.M. Gotto. Wilford Hall Medical Centec San Antonio, TX, USA, University
of North TexaaHealth Science Centac Fort Worth, TX, USA
Characteristic N (%) Lipid m~dl
Gsnder: M 5608 (65) Mean Total-C + S.D. 221 l 21
F 997 (15)
Race: White 5s60 (89) Mean HDL+ S.D, 37* 6
Hispanic 4s7 (7)
Black 206 (3) Mean LDL + S.D. 150 i 17
+ Family Hx CHD 1035 (16) Median TG (Range) 15S (35-620)
Active Smoker 816 (12) Ratio
Hypertension 1439 (22) LDUHDL 4.2 * 0.8
Diabetes 153 (2) Totel-C/HDL 6.1 + 1.1
Unique features of this trial are 1) the inclusion of unstable angina in the
primary endpoint, 2) treatment to a LDL goal lees than current NCEP guide-
lines and 3) a cohort that includes women, elderly and those with ‘normal’
cholesterol, mild-moderately elevated LDL and low HDL. The outcome may
help to clarify the role, in primary prevention, of aggressive LDL reduction to
delay or prevent acute coronary events in a relatively high risk population.
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11032-38I RegionalVariation ihRatea of Cardiac
Catheterization in Stable Angina Patients
Undergoing Myocardial Perfusion Imaging
L.J, Shaw, R. Hachamovitch, G.V. Heller, T.H. MarWick,K.L. Keeler,
M.S. Lauer, D.S. Berman, Ml. Travin, D,D. Miller, for the Emnomics of
Noninvasive Diagnoeis Study Group. Duke UniversiW Durham, NC, USA
Substantial variability in the rates of cardiac Catheterization (CATH) have
been reported. In a recent report from Northern New England, noninvasive
stress testing rates were highly correlated with rates of CATH. We compared
rates of CATH s 90 days in 7,706 stable angina patients referred for strees
perfusion imaging (41% reversible defect, CATH rate= 17%). A mt.dtivariable
risk-adjusted logistic regression analyeiewae performed. A clinical risk index
wae derived based upon a patient’s age, eex, eymptoms, and rick faefors
(35% female, mean age =65 years), CATH rates in 4 hoapitals were 29,22,
12, and 12%for Westcoast, Northeast (NE), Central NE, and Midwest. Ueing
Westcoast as a reference, CATH rates were 20-66% lower in other regions
after controlling for clinical and nuclear variables (see fable).
Region n Odda Ratios of Site vs. Westcoast p value
Westcoaat 2,168 -
Northeast 1,416 0.32 (0.26-0,4) 0.002
Central NE 466 0.S (0.67-0.95) <0,001
Midweat 3,656 0.66 (0.51-0.S6) 0.01
Clinical risk (5%), perfusion defect extent (86%), and hospital cite (9%)
contributed independent information in predicting CATH.
Conckraiorr:Considerable regional variability exists in the uee of esrdiac
catheterization instable angina patients that is unexplained by the underlying
clinical or test risk markers. Other factors (e.g. access, referral patterns)
influence catheterization in this population.
-[ cOmpariSOnAndva,idatiOnofRiSkAdjustment
Modele For Obaerved And Predicted Mortellty of
PTCA
M, Moscucci, J. Seivers, S.G. Ellis, G.T. O’Connor, D.J. Malenka,
The AirForc@TexaeCoronary Atherosclerosis PreventionStudY(AFCAWWd2ApSD.w.M.Muller, E.R. Bates, S.W. Wems, E. Klein, K.A. Eagle. University of
ie a randomized, double-blind placebo-controlled primary preverition trial de-
signed to test the hypothesis that, in addition to a cholesterol lowering diet,
treatment with lovastetin (LOV), toachievea LDLgoalofs llOmg/dl, reduces
the combined incidence of fatal coronary heatt disease (CHD), non-fatal Ml
and uneteble angina.
Over three years, two cites randomized 6605 men and women, with
a mean age of 58 (Range 45-73) to either LOV (20 mg/day) or placebo
(PBO). To reach goal, blinded titration of LOV (and matched PBO) up to 40
mg daily is allowed All participants will be followed until either 320 have
had a primary endpoint or 5 years, whichever occurs last. Independently
adjudicated endpoints will be used for an intention-to-treat analysis. The
baseline characteristics of this study cohort are described below:
Michigan, Ann Arboc Ml, USA
Several risk adjustment models for PTCA mortalily have been recently re-
ported, but external validation. on independent data sets and on high risk
patient populations ie lacking. Between 7/1/94 and 8/1/95, 1476 cxmaeeutive
proeeduree were performed on a high rick patient population characterized
bya high incidence of cardiogenic shock (3.3%) and acute myocardial infarc-
tion (14.3%). in hospital mortality was 3.4% (ehook 48.9%, acute Ml 12.&!’fo,
non Ml 1.4%). Multivariable analysie identified emergency procedure, age,
female gender, eardiogenic shock, pre-procedure administration of iv. NTG,
IABP requirement, LVEDP,and disease eeverity ae independent predietore
of in hospital mortality.Pre-proeedure ueeof aspirin was protective. The area
under the ROC cuwe for mortality wae 0.92, and the Lemeshow-Hosmer
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goodness of fit statistics was not significant, indicating excellent model dis-
crimination. The model generated (M) was compared with the Northern New
England (NNE), and the Cleveland Clinic (CC) models.
Model NNE had a significantly greater ability to predict mortality in thia
patient population when compared with model CC (p < 0.03). Conclusions:
1) Predictive models for PTCA mortality yield variable results when applied
to patient populations other than the one on which the original model was
developad. 2) Although proper risk adjustment may allow comparisons of
different operators and institutions, case mix may confuse interpretation of
1032-40 ClinicalVariableaPredictCoataandResourca
Utilizationin UnatableAngina
J.E. Calvin, L.W. Klein, B.J. Vandenberg, P.Meyer, J.E. Parrillo. Rush
Medical College, Chicago, IL, USA
In a previous study we developad and validated a model based on early
identified clinical factors that pradiefs risk of major cardiac complications in
unstable angina (UA). To determine whether this model could also predict
resource utilization in UA, 470 patients were prospectively evaluated. The
population was orderad on the basis of estimated risk of major complication
(Ml, death or heart failure) and then divided into 3 groups: Low risk: n
= 72, < 2Yo; Medium risk: n = 286, 2.5-15%; and’ High risk: n = 112, >
15%. Admission to CCU, use of surgery, length of stay (LOS) and direct
hospital costs estimated on basis of payor and DRG code were compared.
Results: High risk patients were more frequently admitted to CCU compared
to medium and low risk patients (80Y0vs 8EIY0,P <0.05 and vs 51%, P
< 0.05; respectively), received coronary surgery more often (27Y0vs 15Y0
and 8%, P c 0.05, respectively), had a higher LOS (10 + 7 days vs 8 + 6
days, P <0.05 and 5 + 3 days, P < 0.005) and total hospital cost ($22,120
+ 22,271 vs $14,542 * 11$333,p <13.135and $9102 + 7138, p < 0.05)
then medium and low rfsk patients, respectively. Low risk patienta had lower
LOS and hospital costs than medium risk patienta (P < 0.05). Conclusions.’
Clinical variables available within the first few hours of admission prediet
subsequent resource utilization and hospital cost. This model can support
cliniesl praoflce guidelines by stra~tying patienta into low, madium and high
risk categories which differentiate both outcome and intensity of treatment.
m103241 PredictorsofNotAdministeringThrombolyticTherapyto EligiblePatientswithAMI
J.E. Murillo, J. Chen, Y.Wang, H.M. Krumholz. YaleUniversity SchoO/of
Medicine, New Haven, Cz USA
Although thrombolytic therapy is acost-effeetive treatment of AMI, the utiliza-
tion rates are markedly low among eligible elderly patients. To evaluate the
factors associated with the deeision not to administer thrombolytic therapy
(lT) in the elderly we used the CT cohort of the Cooperative Cardiovascular
Projeet database which contains medical record information for more than
3,000 Medicare patients with AMI.
Among the 756 patients >65 yeara with either ST-segment elevation in
at least two contiguous leads or LBBB not known to be old, no absolute
contraindications to TTand who were not referred for direct PTCA or CABG,
422 (56%) did not recaive thrombolytic therapy. To predict the decision not to
administer 11 we developed a logistic regression model using demographic
and clinical faotora, preadmission madioations, and ECG characteristics as
the candidate variables, as shown below..The area under the ROC curve
was 0.85 suggesting high predictive power.
Variable OR 95%cl P
Ags,eachyear 0.92 0.90-0.95 0.00
ChestPain>6 hrs 0.26 0.1S-0.38 0.00
ChestPainAbsent 0.26 0.16-0.42 0.00
LBBBNotKnownToBeOld 0.03 . 0.01-0.14 0.00
Ttil STElevstionAmplitudes6 mm 0.37 0.23-0.56 0.00
STElevstionin at least 2 Leads 0.60 0.39-0.93 0.02
OldQWaves 0.56 0.3S-Q.62 0.00
Confusion 0,35 0.15-0.84 0.02. . .. .
Coma 0.07 0.01-0.59 0,02
Cone/usion:Variablesthat suggest alargerinfaretion, prforischemicinjury,
greater risk from the therapy and inability to oonsent to therapy explain a
substantial propodion of the decision not to treat with thrombolytic therapy.
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A SimpleClinicalClassificationCanIdentify
Pstientsat RiskforAdvarsePatientOutcomes
(APO)fromDiagnosticandIrrterventional
Procedures:A ProspectiveEvaluation
B.F.Uretsky, F.Wang, S. Black, D. Cutlar, M.J. Davis, C. deFilippi,
R. Farrell, E.J. Maclnerney, Jr., G. Stouffer. The University of TexasMedical
Branch, Galveston, TX, USA
Stratifying procedural risk is important in developing pt care algorithm and
critiquing physician and Iaboratoty outcomes. We prospectively categorized
as high- or low-risk (HR, LR) 5291 consecutive diagnostic (diag) and 729
interventional (interv) eases. HR pts had > 1: diabetes, age >70 yra, Ml c 6
d, NYHA functional Ill, IV, systolic -=90 or >200 mmHg, peripheral vascular
disease, ejection fraction < 25%, creatinine >1.6 mg%, CPR < 7d, inotropic
or mechanical supporL unstable angina, aorfic stenosis, CVA <4 wks, or
bleeding diathesis LR = no HR features.
‘h DiagAPO % IntervAPO
LR(n= 2634) HR(n= 2457) LR (n = 262) HR(n= 467)
Death o 0.12 0 n176----
Ml (Q, non-Q) 0.07 0.12 1.9 3.4
CASG o 0.08 0 7.7+
CVA 0.14 0.44” o 0
Arrhythmia 0.3 0.69” 1.5 1.9
HI 0.03 0.49”” o 0.21
Vascular 0,85 2,5”” 2.3 2n---
AllAPOS 1,4 4,6*” 5,7 11.6**
*p<o.05, **p <0.001 HR va LR; HI = hemodynamicinstabilityrequiringtreatment.
Conclusion: A simple pre-procedural clinical classification can to a great
extent differentiate LR from HR pts for cash-related APO.
These data may be used in defining LR pts for outpatient caths and
evaluating physician and laborato~ performance.
-[ UeeofArtifiCia,NeLJra,NetWOrkstOpredict
MortalityAfterPTCA
R.V. Freeman, D.W.M. Muller, E.R. Bates, S.W. Werns, E. Kline-Rogers,
D.J. Karavite, K.A. Eagle, M. Moscucci. University of Michigan Heart Care
Program, Ann Arboc Ml, USA
Logistic regression models of percutaneous transluminal coronary angio-
plasty (PTCA) mortality are limited by their relative inability to predict out-
comes for individual patients and by low sensitivity. Artificial neural networks
(NN) are computer constructs that can detect complex patterns within a data
set and have been useful in pattern recognition for outcome prediction mcff-
els. This study examined the application of a NN in predicting moflality in
patients undergoing PTCA. A NN was trained on 82 clinical input variables
collected from 1250 consecutive PTCA procedures. Cross validation was
done by dividing the database into three training and test sets. Final valida-
tion was done by running the NN on an additional 224 patients not used in
the training or test phase of NN construction. Positive multivariate predictors
of in-hospital mortality included age, heart failure, renal failure, hemodialysis,
unstable angina, number of diseased vessels, oardiogenic shook, ventricular
tachycardia or fibrillation, LAD lesion, pre-procedure heparin, IABP support
requirement,vasopressor suppofl requirement, and urokinase during the pro-
cedure. Multivariate predictors of in-hospital survival included pre-prooedure
aspirin, pre-procedure t-PA and post-procedure beta-blocker administration.
On the training database, the NN for mortality performed with sensitivity
(s) = S4.1%, a positive prediotiva vaiue (PPV) = 78.7%, and specificity
(sp) = 99.2%. A logistic regression model constructed on the same training
database hads = 31.8%, PPV = 56%, and sp = 99.1%. The NN preserved its
accuracy in the independent validation set withs = 42.9%, PPV = 75.0%, and
Sp = 99.59’..The lower sensitivity seen on the independent validation set was
largely attributable to the low number of events (deaths= 7) observed in the
validation set. Conclusion: Artificial neural networks may provide a valid and
possibly more accurate alternative to conventional logistic regression models
for PTCA mortality assessment, and for predicting outcomes for individual
patients.
m103244 TheFinancialImpactof Stentingis DependentonClinicalEfficacyandPayerMix
P.T.Vaitkus, W.T.Witmer, R.G. Brandenburg. The Univarsify of Vermont,
Burlington, VT USA
Previous studies have focused exclusively on costs of stents, ignoring costs
of prevented complications and ignoring associated revenues. We assess
the cost effectiveness of bailout stenting from the perspective of the provider
organization: how clinically effective does stenting need to be to achieve
